Navigation Links
Biosimilars Market worth $1,954 Million by 2018
Date:11/18/2013

13 to 2018.

By application, oncology is the largest and fastest-growing segment and accounts for a share of 25% of the global Biosimilars Market. This is attributed to the increasing prevalence of oncology along with the rise in aging population and the changing lifestyle.

Europe dominates the global Biosimilars Market with around 40% share in 2013. The factors driving the European market are its well-defined regulatory guidelines; presence of various Biosimilar drugs such as omnitrope, tevagrastim, and binocrits; numerous pipeline products; and more than 15 biologics going off-patent in the coming years. Although the penetration of Biosimilars varies by country, it also depends on various other factors, including local pricing and reimbursement policies, stakeholder influence, and attitudes towards the adoption and use of Biosimilars. Currently, Germany commands the highest share in the European market due to the presence of a reference pricing system.

The U.S., on the other hand, has a very restricted Biosimilars Market owing to the stringent regulatory environment in North America. The Asia-Pacific market is estimated to be the fastest-growing market. Asia-Pacific accounts for an overall share of 29% of the global Biosimilars Market. This large share of the market is mainly due to the semi-regulatory environment of the region that easily approves similar biologics in the market. In addition, low manufacturing costs and the presence of highly skilled expertise at low costs are also factors that make Asia-Pacific a lucrative destination for the Biosimilars Market.

The factors restricting the growth of the market are high manufacturing complexities and costs, stringent regulatory environment in the U.S. and Europe, innovative strategies used by biologic drug manufacturers to protect th
'/>"/>

SOURCE MarketsandMarkets
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Immune Deficiency Foundation Urges FDA To Exempt Immunoglobulin From Biosimilars Pathway
2. Despite Recession, Global Biosimilars Market Grew Over 40% 2010-2011, Set to Reach $3.6 Billion by 2016
3. Biosimilars: Global Markets
4. UBM Conferences Unveils Details for Upcoming Generics and Biosimilars Conference
5. FDA New Guidelines for Biosimilars and Biobetters: An Outlook for 2013
6. Biosimilars Market Expected to Soar
7. Viropro and Oncobiologics Sign Emerging Markets Biosimilars Deal
8. XBiotech Expands Portfolio to Include Biosimilars
9. Recall of Anemia Drug Omontys Rings Alarm Over Biosimilars
10. Seminar Spotlights Key Trends in Biologics and Biosimilars
11. Competitor Analysis: Therapeutic Proteins - Biosimilars, Biobetters & Biosuperiors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... OXFORD, England and SAN JOSE, California ... an international biotechnology company developing antibody-drug conjugates for cancer, today ... its Board of Directors. Dr Reynolds has over 20 years, ... Chief Medical Officer at Seattle Genetics. "I am ...
(Date:1/15/2014)... England , January 15, 2014 A ... win races on the Formula 1 track could help to ... McLaren Applied Technologies (MAT), Stowhealth (a GP surgery based in ... by healthcare provider Simplyhealth. Telemetry technology, which is ...
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains how latent viruses ... is the Epstein Barr Virus (EBV), and one of these ... chronic inflammatory disease that destroys the body’s joints. As predicted ... high concentrations of EBV DNA in their bodies (1). ...
(Date:1/15/2014)... CA (PRWEB) January 15, 2014 ... research solutions, today announced that Lupin Limited, one of ... Freeslate’s CM Protégé PharmD System for high ... Mumbai, India, is focused on a wide range of ...
Breaking Biology Technology:Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3
... STOCKHOLM, September 4 Karolinska Development (publ),today ... has,concluded an extensive clinical study of its candidate drug, ... labor during childbirth.,The promising results of the Phase II ... Karolinska Development,s business strategy. , ...
... BioSpecifics Technologies Corp. (Nasdaq: BSTC ), a ... that BioSpecifics, President, Tom Wegman, will present at the upcoming ... 10, 2009, at 12:05pm ET at the New York Palace ... A live webcast of the presentation can be accessed ...
... , , , , SAN ... the Company will present at the following investor conferences: , , ... 2:45 p.m. Eastern Time (ET) on September 9. , Thomas ... , The 2009 Morgan Stanley Global Healthcare Unplugged Conference in ...
Cached Biology Technology:Karolinska Development Portfolio Company Completes Successful Phase II Clinical Trial 2Karolinska Development Portfolio Company Completes Successful Phase II Clinical Trial 3Gen-Probe to Webcast Four Upcoming Investor Presentations 2
(Date:4/22/2014)... There are all sorts of signaling strategies in nature. ... tails; satin bowbirds build specialized stick structures, called bowers, ... European bitterling males show off bright nuptial coloration during ... to communicate with others. , ... profound fitness implications for individuals that are either signaling ...
(Date:4/22/2014)... must be aware of the broad patent landscape and ... a new paper from Rice University,s Baker Institute for ... the journal Regenerative Medicine , the paper is ... in the case Association for Molecular Pathology (AMP) v. ... court case and rulings garnered discussion in the public ...
(Date:4/22/2014)... have presented Beaumont Health System with prestigious, competitive ... both athletic and nonathletic injuries. , The ... $40,000 grant to fund stem cell-based research that ... a ruptured knee anterior cruciate ligament, or ACL. ... anterior cruciate ligament injury is the over-stretching or ...
Breaking Biology News(10 mins):Best practices in communication for the animal world 2Best practices in communication for the animal world 3New patenting guidelines are needed for biotechnology 2New patenting guidelines are needed for biotechnology 3Beaumont awarded grants to study sports-related injury treatment, improve recovery 2
... Patients with symptomatic moderate asthma who were treated ... antibody, experienced significantly fewer disease exacerbations than individuals ... the first issue for October 2006 of the ... published by the American Thoracic Society. , Trevor ...
... harnessing of 'T-rays' - electromagnetic terahertz waves - which ... varied as biological cell abnormalities and explosives has been announced. ... in Spain have said they have found a way to ... Their findings are set out in a letter published in ...
... theories regarding consciousness, emotion and quality of life ... (ALS, also known as 'Lou Gerhig's disease') are ... interaction. ALS is a progressive disease that destroys ... latest issue of Psychophysiology. The article reviews the ...
Cached Biology News:Monoclonal antibody reduces exacerbations in asthmatics 2T-ray breakthrough could make detecting disease far easier 2Computer with brain connections changing quality of life of paralyzed 2
Glutamate Receptor 5/1a...
Mouse monoclonal [3G8] to MDMA ( Abpromise for all tested applications)....
Fluorescein isothiocyanate (FITC) mouse anti-human IFN-alpha2 50 ug...
Dog polyclonal to Porcine Pancreatic Islets of Langerhans Cells ( Abpromise for all tested applications). Antigen: Tissue / cell preparation (Pig): Sonicated crude membrane fraction of porcine p...
Biology Products: